



Contents lists available at ScienceDirect

Chinese Chemical Letters

journal homepage: [www.elsevier.com/locate/cclet](http://www.elsevier.com/locate/cclet)



Original article

## Cp<sub>2</sub>ZrCl<sub>2</sub>-catalyzed synthesis of 2-aminovinyl benzimidazoles under microwave conditions

Qi Sun<sup>a,\*</sup>, Cheng-Jun Wang<sup>a</sup>, Shan-Shan Gong<sup>a</sup>, Yong-Jian Ai<sup>b</sup>, Hong-Bin Sun<sup>b,\*</sup>

<sup>a</sup>Jiangxi Key Laboratory of Organic Chemistry, Jiangxi Science and Technology Normal University, Nanchang 330013, China

<sup>b</sup>Department of Chemistry, Northeastern University, Shenyang 110819, China

### ARTICLE INFO

#### Article history:

Received 15 August 2014

Received in revised form 15 September 2014

Accepted 13 October 2014

Available online xxx

#### Keywords:

Benzimidazoles

Cp<sub>2</sub>ZrCl<sub>2</sub>

3-Aminoacroleins

Microwave

### ABSTRACT

A microwave-assisted general method for the synthesis of 2-aminovinyl benzimidazoles has been developed. Treatment of the 1,2-phenylenediamines and *N*-arylated/*N,N*-dialkylated 3-aminoacroleins with bis(cyclopentadienyl)zirconium(IV) dichloride (Cp<sub>2</sub>ZrCl<sub>2</sub>) as the catalyst under microwave irradiation for 3–5 min followed by *in situ* MnO<sub>2</sub> oxidation afforded thirteen 2-aminovinyl benzimidazoles in good yields.

© 2014 Qi Sun and Hong-Bin Sun. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.

## 1. Introduction

1,2-Disubstituted benzimidazoles have been recognized as valuable scaffolds in the development of novel pharmaceutical agents and functional materials [1]. In modern drug discovery, a myriad of benzimidazole-based compounds have been synthesized and displayed a variety of pharmacological effects, such as anti-infective, anti-inflammatory, anti-tumor, and anti-diabetic activities [2].

In our previous research on the synthesis of AKT inhibitor IV (ChemBridge 5233705), the unique 2-aminovinyl benzimidazole core structure posed a huge challenge to the existing synthetic methods for benzimidazoles [3]. The conventional condensation of 1,2-phenylenediamines with an *N*-arylated 3-aminoacrolein (**1**) in refluxing ethanol followed by *in situ* oxidation only afforded the products in low yields (<20%) [1,4]. Our attempt to promote the reaction by adding oxidants (e.g., potassium peroxymonosulfate [5], I<sub>2</sub> [6], MnO<sub>2</sub> [7], and 2,3-dichloro-5,6-dicyano-*p*-benzoquinone (DDQ) [8]), acidic catalysts (e.g., BF<sub>3</sub>·Et<sub>2</sub>O [9] and polyphosphoric acid (PPA) [10]), or reducing agents (e.g., SnCl<sub>2</sub> [11]) according to precedent reports failed to generate the desired product. Interestingly, in our search for potential metal catalyst [12], we found that ZrOCl<sub>2</sub>·8H<sub>2</sub>O and ZrCl<sub>4</sub> exhibited a

dramatic catalytic effect on the reactions of 1,2-phenylenediamines with **1** and improved the yields to 50%–70% [3]. However, the understanding of this metal-catalyzed condensation/cyclization reaction is still very limited and the extension of this approach to *N,N*-dialkylated 3-aminoacroleins has never been explored. We report herein a microwave-assisted method for the synthesis of a diversity of 2-aminovinyl benzimidazoles with bis(cyclopentadienyl)zirconium(IV) dichloride (Cp<sub>2</sub>ZrCl<sub>2</sub>) as a more effective catalyst.

## 2. Experimental

1,2-Phenylenediamines (**7**–**12**) were prepared according to the reported procedures [3]. All NMR spectra were obtained with a 400 MHz instrument with chemical shifts reported in parts per million (ppm,  $\delta$ ) and referenced to CDCl<sub>3</sub> or DMSO-*d*<sub>6</sub>. IR spectra were recorded on a FT-IR spectrometer. High-resolution mass spectra were obtained with a TOFQ mass spectrometer and reported as *m/z*. Microwave reactions were performed on an Anton Paar Monowave 300 instrument with 30 mL reaction vials. The characterization data of known compounds (**1**–**3**, **5**, and **13**–**18**) and <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra of new compounds (**4**, **6**, and **19**–**25**) were included in the Supporting information.

### 2.1. General procedure for the synthesis of 3-aminoacroleins (**1**–**6**)

To a solution of amine (10 mmol) and propargyl alcohol (20 mmol) in toluene (20 mL) was slowly added activated MnO<sub>2</sub>

\* Corresponding author.

E-mail addresses: [sunqi96@tsinghua.org.cn](mailto:sunqi96@tsinghua.org.cn) (Q. Sun), [sunhb@mail.neu.edu.cn](mailto:sunhb@mail.neu.edu.cn) (H.-B. Sun).

<http://dx.doi.org/10.1016/j.ccllet.2014.11.014>

1001-8417/© 2014 Qi Sun and Hong-Bin Sun. Published by Elsevier B.V. on behalf of Chinese Chemical Society. All rights reserved.

(200 mmol) at 0 °C. The reaction was stirred for 2 h and then warmed up to 22 °C. After 24 h, MnO<sub>2</sub> was filtered off and washed with ethyl acetate (10 mL). The combined filtrate was concentrated *in vacuo*. Flash column chromatography on silica gel afforded the product.

(*E*)-3-*N*-Cyclohexyl-*N*-ethylaminoacrolein (**4**): Yellow solid; mp 58–60 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.94–1.26 (m, 6H), 1.26–1.40 (m, 2H), 1.50–1.61 (m, 1H), 1.74 (d, 4H, *J* = 10.6 Hz), 2.90–3.19 (m, 3H), 5.06 (dd, 1H, *J*<sub>1</sub> = 8.7 Hz, *J*<sub>2</sub> = 12.5 Hz), 6.98 (d, 1H, *J* = 12.8 Hz), 8.92 (d, 1H, *J* = 8.6 Hz); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 12.3, 25.0, 25.5, 32.3, 42.1, 65.1, 100.9, 156.7, 189.1; IR (neat, cm<sup>-1</sup>): ν<sub>max</sub> 2927, 2848, 1595, 1442, 1350, 1161, 893, 795; HRMS (ESI<sup>+</sup>): *m/z* calcd. for C<sub>11</sub>H<sub>19</sub>NO [M+H]<sup>+</sup>: 182.1467; found: 182.1458.

(*E*)-3-(4-Methylpiperazin-1-yl)acrylaldehyde (**6**): Yellow oil; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.88–1.99 (m, 3H), 2.00–2.21 (m, 4H), 2.74–3.28 (m, 4H), 4.76–4.89 (m, 1H), 6.64–6.78 (m, 1H), 8.65–8.75 (m, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 44.4, 45.3, 53.5, 100.4, 158.4, 188.6; IR (neat, cm<sup>-1</sup>): ν<sub>max</sub> 2944, 1597, 1435, 1317, 1173, 767; HRMS (ESI<sup>+</sup>): *m/z* calcd. for C<sub>8</sub>H<sub>14</sub>N<sub>2</sub>O [M+H]<sup>+</sup>: 155.1106; found: 155.1112.

## 2.2. General procedure for the synthesis of 2-aminovinyl benzimidazoles (**13–25**)

To a solution of 1,2-phenylenediamine (0.1 mmol) and 3-aminoacrolein (0.12–0.15 mmol) in ethanol (15 mL) was added Cp<sub>2</sub>ZrCl<sub>2</sub> (0.05 mmol). The solution was subjected to microwave heating at 80 °C for 3–5 min. Then, MnO<sub>2</sub> (0.5 mmol) was added, and the reaction was stirred for 5 min. MnO<sub>2</sub> was filtered off and washed with ethanol (5 mL). The combined filtrate was concentrated *in vacuo*. Flash column chromatography on silica gel afforded the product.

[(*E*)-2-(5-Benzothiazole-2-yl-1-phenyl-1H-benzimidazole-2-yl)ethenyl]isopropylphenylamine (**19**): Yellow solid; mp 172–174 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 1.24 (d, 6H, *J* = 6.7 Hz), 3.84–3.98 (m, 1H), 4.84 (d, 1H, *J* = 13.3 Hz), 7.08 (d, 1H, *J* = 8.4 Hz), 7.13 (d, 2H, *J* = 7.8 Hz), 7.21 (dd, 1H, *J*<sub>1</sub> = *J*<sub>2</sub> = 7.2 Hz), 7.27–7.52 (m, 9H), 7.86 (d, 1H, *J* = 7.9 Hz), 7.93 (d, 1H, *J* = 8.4 Hz), 8.00–8.10 (m, 2H), 8.27 (s, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 21.8, 54.7, 84.2, 109.3, 117.0, 120.5, 121.5, 122.9, 124.6, 126.1, 126.9, 127.3, 128.0, 128.1, 128.5, 129.3, 129.7, 135.1, 135.9, 138.7, 142.5, 144.1, 145.0, 154.5, 156.6, 169.6; IR (neat, cm<sup>-1</sup>): ν<sub>max</sub> 3651, 1619, 1586, 1502, 1460, 1412, 1071, 869, 754; HRMS (ESI<sup>+</sup>): *m/z* calcd. for C<sub>31</sub>H<sub>26</sub>N<sub>4</sub>S [M+H]<sup>+</sup>: 487.1878; found: 487.1869.

[(*E*)-2-(5-Benzothiazole-2-yl-1-phenyl-1H-benzimidazole-2-yl)ethenyl]methylbenzylamine (**20**): Yellow solid; mp 72–74 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 2.72 (s, 3H), 4.36 (s, 2H), 4.84 (d, 1H, *J* = 13.0 Hz), 7.08 (d, 1H, *J* = 8.4 Hz), 7.20 (d, 2H, *J* = 7.2 Hz), 7.27–7.36 (m, 4H), 7.38–7.51 (m, 4H), 7.52–7.63 (m, 2H), 7.87 (d, 1H, *J* = 7.9 Hz), 7.94 (d, 1H, *J* = 8.2 Hz), 8.05 (d, 2H, *J* = 10.6 Hz), 8.27 (s, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 36.7, 59.5, 81.7, 109.3, 116.9, 120.5, 121.5, 122.9, 124.7, 126.1, 127.5, 127.6, 127.8, 128.2, 128.7, 128.8, 129.9, 135.2, 136.1, 136.9, 139.9, 144.1, 147.7, 154.5, 156.7, 169.7; IR (neat, cm<sup>-1</sup>): 3674, 1626, 1595, 1497, 1466, 1276, 1052, 895, 755; HRMS (ESI<sup>+</sup>): *m/z* calcd. for C<sub>34</sub>H<sub>24</sub>N<sub>4</sub>S [M+H]<sup>+</sup>: 473.1722; found: 473.1716.

[(*E*)-2-(5-Benzothiazole-2-yl-1-phenyl-1H-benzimidazole-2-yl)ethenyl]ethylcyclohexylamine (**21**): Yellow solid; mp 132–134 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 0.98–1.16 (m, 3H), 1.18–1.36 (m, 3H), 1.37–1.52 (m, 2H), 1.58–1.70 (m, 1H), 1.82 (d, 4H, *J* = 10.8 Hz), 3.03–3.31 (m, 3H), 4.74 (d, 1H, *J* = 13.1 Hz), 7.05 (d, 1H, *J* = 8.3 Hz), 7.31 (dd, 1H, *J*<sub>1</sub> = *J*<sub>2</sub> = 7.6 Hz), 7.39–7.50 (m, 4H), 7.56 (dd, 2H, *J*<sub>1</sub> = *J*<sub>2</sub> = 7.6 Hz), 7.84 (d, 1H, *J* = 3.4 Hz), 7.87 (s, 1H), 7.90 (d, 1H, *J* = 8.4 Hz), 8.03 (d, 1H, *J* = 8.2 Hz), 8.23 (s, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 13.3, 25.4, 26.0, 32.4, 41.2, 64.1, 79.8, 109.0, 116.5, 120.1,

121.5, 122.8, 124.6, 126.0, 127.6, 128.0, 128.5, 129.8, 135.1, 136.3, 138.9, 144.3, 144.7, 154.5, 157.6, 169.8; IR (neat, cm<sup>-1</sup>): 3674, 1622, 1497, 1460, 1395, 1275, 1218, 1067, 809, 754; HRMS (ESI<sup>+</sup>): *m/z* calcd. for C<sub>30</sub>H<sub>30</sub>N<sub>4</sub>S [M+H]<sup>+</sup>: 479.2191; found: 479.2184.

4-[(*E*)-2-(5-Benzothiazole-2-yl-1-phenyl-1H-benzimidazole-2-yl)ethenyl]morpholine (**22**): Yellow solid; mp 172–174 °C (decomp.); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 3.12–3.24 (m, 4H), 3.71 (t, 4H, *J* = 4.6 Hz), 4.95 (d, 1H, *J* = 13.3 Hz), 7.10 (d, 1H, *J* = 8.4 Hz), 7.34 (dd, 1H, *J*<sub>1</sub> = *J*<sub>2</sub> = 7.7 Hz), 7.39–7.49 (m, 3H), 7.52 (dd, 1H, *J*<sub>1</sub> = *J*<sub>2</sub> = 7.2 Hz), 7.60 (dd, 2H, *J*<sub>1</sub> = *J*<sub>2</sub> = 7.2 Hz), 7.73 (d, 1H, *J* = 13.3 Hz), 7.88 (d, 1H, *J* = 7.9 Hz), 7.95 (d, 1H, *J* = 8.3 Hz), 8.05 (d, 1H, *J* = 8.0 Hz), 8.26 (s, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 48.6, 66.3, 83.3, 109.5, 117.2, 120.9, 121.6, 123.0, 124.8, 126.2, 127.7, 128.5, 128.9, 130.1, 135.3, 136.0, 138.9, 144.0, 147.0, 154.6, 156.1, 169.5; IR (neat, cm<sup>-1</sup>): 3674, 1624, 1498, 1443, 1392, 1081, 890, 759; HRMS (ESI<sup>+</sup>): *m/z* calcd. for C<sub>26</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub> [M+H]<sup>+</sup>: 439.1514; found: 439.1506.


4-Methyl-(*E*)-2-(5-benzothiazole-2-yl-1-phenyl-1H-benzimidazole-2-yl)ethenyl]piperazine (**23**): Yellow solid; mp 180–182 °C (decomp.); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 2.29 (s, 3H), 2.40 (t, 4H, *J* = 4.7 Hz), 3.19 (t, 4H, *J* = 4.6 Hz), 4.89 (d, 1H, *J* = 13.2 Hz), 7.07 (d, 1H, *J* = 8.4 Hz), 7.33 (dd, 1H, *J*<sub>1</sub> = *J*<sub>2</sub> = 7.7 Hz), 7.37–7.47 (m, 3H), 7.50 (dd, 1H, *J*<sub>1</sub> = *J*<sub>2</sub> = 7.2 Hz), 7.58 (dd, 2H, *J*<sub>1</sub> = *J*<sub>2</sub> = 7.4 Hz), 7.74 (d, 1H, *J* = 13.2 Hz), 7.87 (d, 1H, *J* = 7.9 Hz), 7.93 (d, 1H, *J* = 8.4 Hz), 8.03 (d, 1H, *J* = 8.1 Hz), 8.24 (s, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 46.3, 48.3, 54.4, 82.3, 109.4, 117.0, 120.6, 121.5, 122.9, 124.7, 126.1, 127.6, 128.2, 128.8, 130.0, 135.2, 136.0, 138.8, 144.0, 146.8, 154.5, 156.5, 169.6; IR (neat, cm<sup>-1</sup>): 3680, 1623, 1495, 1408, 1380, 1240, 1056, 899, 751; HRMS (ESI<sup>+</sup>): *m/z* calcd. for C<sub>27</sub>H<sub>25</sub>N<sub>5</sub>S [M+H]<sup>+</sup>: 452.1831; found: 452.1841.

4-[(*E*)-2-Phenyl-1H-benzimidazole-2-yl]ethenyl]morpholine (**24**): Yellow solid; mp 64–66 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 3.11 (t, 4H, *J* = 4.8 Hz), 3.68 (t, 4H, *J* = 4.8 Hz), 4.97 (d, 1H, *J* = 13.4 Hz), 7.00–7.09 (m, 2H), 7.19 (dd, 1H, *J*<sub>1</sub> = *J*<sub>2</sub> = 7.6 Hz), 7.39 (d, 2H, *J* = 7.2 Hz), 7.48 (dd, 1H, *J*<sub>1</sub> = *J*<sub>2</sub> = 7.3 Hz), 7.56 (dd, 2H, *J*<sub>1</sub> = *J*<sub>2</sub> = 7.2 Hz), 7.63 (d, 1H, *J* = 7.6 Hz), 7.66 (d, 1H, *J* = 13.2 Hz); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 48.5, 66.3, 84.0, 109.2, 117.5, 121.0, 122.4, 127.7, 128.5, 129.8, 136.4, 136.6, 143.6, 146.3, 154.3; IR (neat, cm<sup>-1</sup>): 3406, 1624, 1585, 1459, 1381, 1254, 1027, 956, 767; HRMS (ESI<sup>+</sup>): *m/z* calcd. for C<sub>19</sub>H<sub>19</sub>N<sub>3</sub>S [M+H]<sup>+</sup>: 306.1528; found: 306.1519.

[(*E*)-2-(5-Benzothiazole-2-yl-1-(4-methoxyphenyl)-1H-benzimidazole-2-yl)ethenyl]methylbenzylamine (**25**): Yellow solid; mp 76–78 °C; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 2.71 (s, 3H), 3.88 (s, 3H), 4.36 (s, 2H), 4.80 (d, 1H, *J* = 13.0 Hz), 7.04 (d, 3H, *J* = 8.3 Hz), 7.20 (d, 2H, *J* = 7.6 Hz), 7.27–7.36 (m, 6H), 7.45 (dd, 1H, *J*<sub>1</sub> = *J*<sub>2</sub> = 7.3 Hz), 7.87 (d, 1H, *J* = 7.9 Hz), 7.94 (d, 1H, *J* = 8.3 Hz), 8.02 (d, 1H, *J* = 8.0 Hz), 8.04–8.06 (m, 1H), 8.25 (s, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>): δ 29.8, 36.6, 55.7, 59.5, 81.8, 109.2, 115.1, 116.8, 120.4, 121.5, 122.9, 124.6, 126.1, 127.5, 127.8, 128.0, 128.6, 128.8, 135.2, 136.9, 139.3, 144.1, 147.5, 154.5, 157.1, 159.6, 169.8; IR (neat, cm<sup>-1</sup>): 3046, 1631, 1514, 1467, 1278, 1027, 839, 760; HRMS (ESI<sup>+</sup>): *m/z* calcd. for C<sub>31</sub>H<sub>26</sub>N<sub>4</sub>O<sub>2</sub> [M+H]<sup>+</sup>: 503.1827; found: 503.1819.

## 3. Results and discussion

To explore the scope of the reaction, a series of *N*-arylated and *N,N*-dialkylated 3-aminoacroleins **1–6** were synthesized via a modified procedure described in Scheme 1 [13]. Treatment of 1.0 equiv. of propargyl alcohol with 0.5 equiv. of amino compounds in the presence of 10 equiv. of activated MnO<sub>2</sub> afforded **1–6** in 53%–75% yields. Compared to the δ<sub>H</sub> values of the aldehyde protons of benzaldehyde (10.02), *n*-hexyl aldehyde (9.66), and cinnamaldehyde (9.74), the δ<sub>H</sub> value of 3-(*N*-phenyl-*N*-methyl)aminoacrolein (**1**) was much smaller (9.27), indicating that the electropositivity of the carbonyl group was remarkably lowered due to the conjugation of electron-donating aniline moiety. This result explained why the conventional condensation methods for regular aldehyde



**Scheme 1.** A general method for the synthesis of *N*-arylated and *N,N*-dialkylated 3-aminoacroleins **1–6**.

substrates were not applicable on **1**. The aldehyde proton peaks of *N,N*-dialkyl 3-aminoacroleins **3–6** moved toward higher magnetic field (8.92–8.74), suggesting that *N,N*-dialkylated 3-aminoacroleins might be less reactive toward nucleophiles because of the higher electron-donating capability of the dialkylamino moiety.


Compared to thermal heating, microwave irradiation has showed positive effects on both reaction time and yield in precedent synthesis of benzimidazoles [7,14]. In our research, we explored the possibility to improve the synthetic efficacy of 2-aminovinyl benzimidazoles under microwave conditions. In the preliminary experiments, the ethanol solution of **1** (1.2 equiv.) and 4-benzothiazol-2-yl-*N*<sup>1</sup>-phenylbenzene-1,2-diamine (**7**, 1.0 equiv.) with different Lewis acids (0.5 equiv.) was irradiated with microwave at 80 °C for 3 min. To the reaction solution was then added activated MnO<sub>2</sub> (5.0 equiv.) to generate the 2-aminovinyl benzimidazole **13**. The experimental results listed in Table 1 (entries 1–16) showed that most tested Lewis acids resulted in no reaction or only gave **13** in poor yields. In contrast, all of the zirconium(IV) salts exhibited comparable catalytic effect on the formation of **13**. Compared to the previously reported ZrCl<sub>4</sub> and ZrOCl<sub>2</sub>·8H<sub>2</sub>O, Cp<sub>2</sub>ZrCl<sub>2</sub>-catalyzed reaction afforded **13** in even

higher yield (78%). The solvent effect on this reaction was also investigated. The data in Table 1 (entries 16–22) showed that the catalytic effect of Cp<sub>2</sub>ZrCl<sub>2</sub> was specific in ethanol and not simply related the dielectric constants and polarity of the solvents, suggesting that Zr(IV) salts might go through a solvolysis process and ethanol was possibly involved in reactive metal complex that promoted the condensation of **1** and **7**. It was also confirmed that a minimum of 0.5 equiv. of Cp<sub>2</sub>ZrCl<sub>2</sub> was required for complete consumption of **7**.


As shown in Scheme 2, the reactions of a variety of 1,2-phenylenediamines **7–12** and *N*-arylated 3-aminoacroleins **1** and **2** with Cp<sub>2</sub>ZrCl<sub>2</sub> as the catalyst under microwave conditions followed by MnO<sub>2</sub> oxidation yielded the corresponding 2-aminovinyl benzimidazoles **14–19** in 70%–76% yields. In contrast, when *N,N*-dialkylated 3-aminoacroleins **3–6** were applied, a higher equivalent of 3-aminoacroleins (1.5 equiv.) and longer microwave irradiation time (5 min) were required to afford **20–25** in good yields (68%–76%). These results were in agreement with our speculation that *N,N*-dialkylated 3-aminoacroleins were less reactive than their *N*-arylated counterparts. Moreover, control experiments based on thermal heating were also performed. The reaction of **7** and *N*-arylated 3-aminoacrolein **1** in refluxing ethanol needed 30 min for the first step, whereas that of **7** and *N,N*-dialkylated 3-aminoacrolein **5** required 2 h. Compared to thermal heating, microwave irradiation also improved the yields of **13** (72% for thermal heating and 78% for MW) and **22** (60% for thermal heating and 70% for MW).

TLC monitoring of the first step reaction of **1** and **7** showed that the major product spot was an orange-colored polar band, which was unstable to isolate. After MnO<sub>2</sub> oxidation, it was completely converted to the less polar spot of **13**. Due to the fact that benzimidazoline intermediate is typically less polar than the corresponding benzimidazole, we proposed that the condensation of **1** and **7** favored the formation of imine instead of the cyclized

**Table 1**  
Effects of Lewis acid and solvent on the synthesis of 2-aminovinyl benzimidazole **13**.



Entry	Lewis acid	Solvent	Isolated yield (%)
1	None	EtOH	n.r.
2	ZnCl <sub>2</sub>	EtOH	n.r.
3	CuCl <sub>2</sub>	EtOH	n.r.
4	MgCl <sub>2</sub>	EtOH	n.r.
5	NiCl <sub>2</sub>	EtOH	n.r.
6	InCl <sub>3</sub>	EtOH	n.r.
7	CeCl <sub>3</sub>	EtOH	5
8	AlCl <sub>3</sub>	EtOH	13
9	FeCl <sub>3</sub>	EtOH	28
10	TiCl <sub>4</sub>	EtOH	15
11	Et <sub>2</sub> O·BF <sub>3</sub>	EtOH	18
12	Zr(NO <sub>3</sub> ) <sub>2</sub>	EtOH	54
13	Zr(NO <sub>3</sub> ) <sub>4</sub>	EtOH	62
14	ZrOCl <sub>2</sub> ·8H <sub>2</sub> O	EtOH	67
15	ZrCl <sub>4</sub>	EtOH	72
16	Cp <sub>2</sub> ZrCl <sub>2</sub>	EtOH	78
17	Cp <sub>2</sub> ZrCl <sub>2</sub>	CH <sub>2</sub> Cl <sub>2</sub>	n.r.
18	Cp <sub>2</sub> ZrCl <sub>2</sub>	THF	n.r.
19	Cp <sub>2</sub> ZrCl <sub>2</sub>	CH <sub>3</sub> CN	n.r.
20	Cp <sub>2</sub> ZrCl <sub>2</sub>	Toluene	n.r.
21	Cp <sub>2</sub> ZrCl <sub>2</sub>	DMF	n.r.
22	Cp <sub>2</sub> ZrCl <sub>2</sub>	DMSO	n.r.



Scheme 2. Microwave-assisted synthesis of 2-aminovinyl benzimidazoles **14–25** with  $\text{Cp}_2\text{ZrCl}_2$  as the catalyst.

benzimidazoline intermediate in the presence of  $\text{Cp}_2\text{ZrCl}_2$ . Only after oxidant was added to transform the benzimidazoline intermediate to **13**, the cyclization reaction was driven to completion.

#### 4. Conclusion

In summary, we developed a general method for the synthesis of a variety of 2-aminovinyl benzimidazole compounds. Our experimental results showed that  $\text{Cp}_2\text{ZrCl}_2$  exhibited the best catalytic effect on the condensation of 1,2-phenylenediamine and 3-aminoacrolein substrates under microwave conditions. This novel synthetic method provides facile and efficient access to diverse 2-aminovinyl benzimidazoles and will facilitate the investigation of their applications in pharmaceutical and material sciences.

#### Acknowledgments

We thank the National Natural Science Foundation of China (Nos. 21262014 to Q. Sun and 21003018 to H.-B. Sun), Key Project of Chinese Ministry of Education (No. 212092), and Research Funds (Nos. ky2012zy08 and 2013QNBjRC001) from JXSTNU for financial support.

#### Appendix A. Supplementary data

Supplementary data associated with this article can be found in the online version, at <http://dx.doi.org/10.1016/j.ccllet.2014.11.014>.

#### References

[1] (a) P.N. Preston, Synthesis, reactions, and spectroscopic properties of benzimidazoles, *Chem. Rev.* 74 (1974) 279–314;

- (b) L.C.R. Carvalho, E. Fernandes, M.M.B. Marques, Developments towards regioselective synthesis of 1,2-disubstituted benzimidazoles, *Chem. Eur. J.* 17 (2011) 12544–12555.
- [2] M. Alamgir, D.S.C. Black, N. Kumar, Synthesis, reactivity and biological activity of benzimidazoles, *Top. Heterocycl. Chem.* 21 (2007) 87–118.
- [3] Q. Sun, R.Z. Wu, S.T. Cai, et al., Synthesis and biological evaluation of analogues of AKT (protein kinase B) inhibitor-IV, *J. Med. Chem.* 54 (2011) 1126–1139.
- [4] J.M. Smith, V. Krchnak, A solid phase traceless synthesis of benzimidazoles with three combinatorial steps, *Tetrahedron Lett.* 40 (1999) 7633–7636.
- [5] P.L. Beaulieu, B. Hache, E. von Moos, A practical oxone-mediated, high-throughput, solution-phase synthesis of benzimidazoles from 1,2-phenylenediamines and aldehydes and its application to preparative scale synthesis, *Synthesis* (2003) 1683–1692.
- [6] P. Gogoi, D. Konwar, An efficient and one-pot synthesis of imidazolines and benzimidazoles via anaerobic oxidation of carbon–nitrogen bonds in water, *Tetrahedron Lett.* 47 (2006) 79–82.
- [7] S.Y. Kim, K.H. Park, Y.K. Chung, Manganese(IV) dioxide-catalyzed synthesis of quinoxalines under microwave irradiation, *Chem. Commun.* (2005) 1321–1323.
- [8] J.P. Mayer, G.S. Lewis, C. McGee, et al., Solid-phase synthesis of benzimidazoles, *Tetrahedron Lett.* 39 (1998) 6655–6658.
- [9] R.R. Nagawade, D.B. Shinde,  $\text{BF}_3 \cdot \text{OEt}_2$  promoted solvent-free synthesis of benzimidazole derivatives, *Chin. Chem. Lett.* 17 (2006) 453–456.
- [10] M.B. Wallace, J. Feng, Z.Y. Zhang, et al., Structure-based design and synthesis of benzimidazole derivatives as dipeptidyl peptidase IV inhibitors, *Bioorg. Med. Chem. Lett.* 18 (2008) 2361–2362.
- [11] L.P. Duan, Q. Li, N.B. Wu, et al., Synthesis of 2,5-disubstituted benzimidazole using  $\text{SnCl}_2$ -catalyzed reduction system at room temperature, *Chin. Chem. Lett.* 25 (2014) 155–158.
- [12] (a) Z.H. Zhang, L. Yin, Y.M. Wang, An expeditious synthesis of benzimidazole derivatives catalyzed by Lewis acids, *Catal. Commun.* 8 (2007) 1126–1131; (b) R.R. Nagawade, D.B. Shinde, Zirconium(IV) chloride-promoted synthesis of benzimidazole derivatives, *Russ. J. Org. Chem.* 42 (2006) 453–454.
- [13] K. Deo, S. Kanwar, A. Pandey, et al., Process for the preparation of N-methyl anilino acrolein, WO 2005090256, *Chem. Abstr.* 145 (2006) 292712.
- [14] (a) G. Navarrete-Vázquez, H. Moreno-Díaz, F. Aguirre-Crespo, et al., Design, microwave-assisted synthesis, and spasmolytic activity of 2-(alkoxyaryloxy)-1H-benzimidazole derivatives as constrained stilbene bioisosteres, *Bioorg. Med. Chem. Lett.* 16 (2006) 4169–4173; (b) R.G. Jacob, L.G. Dutra, C.S. Radatz, et al., Synthesis of 1,2-disubstituted benzimidazoles using  $\text{SiO}_2/\text{ZnCl}_2$ , *Tetrahedron Lett.* 50 (2009) 1495–1497.